Gemcitabine: 40 Real Stories

40 stories match gemcitabine. 39 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Metastatic Breast Cancer Treatment Caused Severe Circulation Problems in Her Fingers and Toes

Patient Info: Anonymized, Female | Stage IV

Biomarkers: HER2-positive; ER-negative; PR-negative

The digital ischaemia improved after gemcitabine was stopped, without revascularisation, debridement or amputation, although a small necrotic fingertip area persisted at 3 months. Metastatic breast cancer treatment continued with further systemic lines after progression.

PubMed Central
OutcomeLiving With Cancer / Ongoing Treatment
A patient, who was diagnosed with Ovarian CancerOvarian Cancer

Metastatic Clear Cell Ovarian Cancer Complicated by Treatment-Related Sarcoidosis

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Metastatic Site: peritoneum

During a treatment holiday, biopsy and laboratory evaluation showed treatment-related sarcoidosis rather than ovarian-cancer spread in the enlarged lymph nodes. After prednisone, the sarcoidosis resolved and imaging showed no progression of the clear cell ovarian cancer; she remained clinically well 4 months later.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Ovarian AdenocarcinomaOvarian Cancer

Kidney Complications After Treatment for Stage IV Ovarian Cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: peritoneum|left lymph node

No further ovarian-cancer progression was observed during the 10 months after kidney biopsy. The nephrotic syndrome reached partial remission after immunosuppressive treatment was stopped and supportive care continued.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

A durable response to trastuzumab in heavily pretreated metastatic breast cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor ER-positive and PR-positive. Metastatic liver biopsy ER-negative and PR-negative with HER2 IHC 1+ and nonamplified. Later biopsy ER and PR weakly positive at 5%–10%, HER2 IHC 1+ and nonamplified, and ERBB3 p. with evidence of HER2/HER3 pathway activation.

Metastatic Site: lungs; hilar and mediastinal lymph nodes; liver; bone

She had ongoing benefit for more than 10 months on trastuzumab and capecitabine, with improved symptoms, lower tumor markers, and a confirmed partial response.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Ovarian CancerOvarian Cancer

Stable Brain Metastases During Niraparib Maintenance for Ovarian Cancer

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: CA-125 4019 kU/L; pathogenic germline BRCA1 mutation

Metastatic Site: brain

After 17 months of niraparib, her brain metastases remained stable. She had a performance status of 0 and reported a full, normal quality of life.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Osimertinib Improved Spinal Cord Metastases in Long-Standing Lung Cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Initial surgical specimen: no detected EGFR mutation and ALK-negative. Later pleural-fluid tumor: acquired EGFR T790M mutation with no other detected EGFR mutation.

Metastatic Site: cervical and mediastinal lymph nodes; bone; brain;…

Osimertinib improved neurologic function and kept the lung cancer stable for 14 months; he later died from bacterial pneumonia.

PubMed Central
OutcomeIn Memory
AO
Ovarian Cancer

Advanced Ovarian Cancer Presenting With Dermatomyositis

Patient Info: Anonymized, Female, 50s

Biomarkers: CA-125 3169 at diagnosis; later CA-125 rise with progression

After a partial response to second-line chemotherapy, nodal disease progressed again 5 months later and liposomal doxorubicin was planned.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Delayed Adrenal Insufficiency After Nivolumab for Stage IV Lung Cancer

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR unmutated; ALK unmutated; ROS1 unmutated

His weakness, fatigue, weight loss, and orthostatic hypotension resolved after hormone replacement, and he returned home independently.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIB lung adenocarcinoma with separate papillary renal cell carcinoma: doing well more than 6 years after revised diagnosis

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Lung tumor: TTF-1-positive; PET-avid. Kidney lesion: PET-negative; later papillary renal cell carcinoma. No lung molecular biomarkers reported.

As of February 2014, she was doing well more than 6 years after the initial diagnosis, after the diagnosis was revised from presumed Stage IV lung cancer to Stage IIIB lung adenocarcinoma plus a separate papillary renal cell carcinoma.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV EBV-positive lymphoepithelioma-like lung cancer with brain metastasis

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EBV-positive by in-situ hybridization

Metastatic Site: brain, retroperitoneal/posterior mediastinal soft…

Remained well and disease-free 6 months after resection of the retroperitoneal/posterior mediastinal metastasis and 8 years after initial presentation.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Ovarian CancerOvarian Cancer

Recurrent Stage III Ovarian Cancer Complicated by Severe Kidney Injury

Patient Info: Anonymized, female, 70+ | Stage III

After further intra-abdominal cancer progression and severe kidney injury, she developed seizures, encephalopathy, and limb ischemia and died 1 week after hospitalization in May 2011.

PubMed Central
OutcomeIn Memory